CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Clinical advantages of CRRT (Continuous Renal Replacement Therapy)
4.1.2. Increasing prevalence of acute renal failure and congestive heart failure
4.1.3. Increasing global incidence of AKI and sepsis
4.1.4. Growing number of ICU patients
4.1.5. Increasing incidence of volume overload, uremia, and hyperkalemia
4.2. Market Restraints & Challenges
4.2.1. Strict regulatory guidelines and a shortage of trained ICU nurses
4.2.2. High procedural cost & complexity of CRRT
4.2.3. Low reimbursement scenario and lack of awareness about CRRT benefits
4.3. Market Opportunities
4.3.1. Continuing research to establish safety and efficacy profile of CRRT
4.3.2. Development of CRRT system for pediatric patients
4.3.3. Emerging markets and untapped growth potential
CHAPTER 5 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET – BY PRODUCT
5.1. Dialysates and Replacement Fluids
5.1.1. Disposables
5.1.1.1. Hemofilters
5.1.1.2. Bloodline Sets (Tubing Sets)
5.1.1.3. Others
5.1.2. Systems
CHAPTER 6 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET – BY MODALITY
6.1. Continuous Venovenous Hemofiltration
6.2. Continuous Venovenous Hemodiafiltration
6.3. Continuous Venovenous Hemodialysis
6.4. Slow Continuous Ultrafiltration
CHAPTER 7 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET – BY END USER
7.1. Hospitals
7.2. Clinics
7.3. Homes
CHAPTER 8 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET - COMPANY PROFILES
9.1. Nikkiso Co., Ltd.
9.2. Fresenius Medical Care AG & Co. KgaA
9.3. Baxter International Inc.
9.4. Nxstage Medical, Inc.
9.5. B. Braun Melsungen AG
9.6. Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Corporation)
9.7. BeLLCo S.R.L. (A Part of Medtronic PLC)
9.8. Toray Medical Co., Ltd.
9.9. Infomed Sa
9.10. Medica S.P.A.
9.11. Medical Components, Inc.
9.12. Medites Pharma Spol. S.R.O.
9.13. Medtronic PLC
9.14. SWS Hemodialysis Care Co. Ltd.
9.15. Ningbo Tianyi Medical Appliance Co., Ltd.
CHAPTER 10 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET - COMPETITIVE LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11 MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12 APPENDIX
12.1. List of Tables
12.2. List of Figures
